title: Dorzolamide cyclodextrin nanoparticle suspension eye drops and Trusopt in rabbit.
abstract: OBJECTIVE
  Dorzolamide nanoparticle γ-cyclodextrin eye drops may prolong the effect of dorzolamide on intraocular pressure. We test whether the nanoparticle drops have an irritating or toxic effect on the eye in an in vivo rabbit model.
  
  
  METHODS
  Eighteen pigmented rabbits were divided into 4 groups receiving dorzolamide nanoparticle γ-cyclodextrin eye drops×1/day or×2/day, Trusopt® (dorzolamide HCl)×3/day, and untreated controls that received no drops. The rabbits received treatment for 1 month. After sacrifice, 33 eyes and 25 Harderian glands were evaluated for histopathology in a masked way.
  
  
  RESULTS
  Mild inflammation was seen in 19/31 eyes and 13/23 Harderian glands. The difference in inflammation (n=eyes/n=glands)between the γ-cyclodextrin nanoparticle eye drops×1/day (n=5/5),×2/day (n=5/3), Trusopt (n=7/4), or untreated control (n=2/0) groups was nonsignificant in both eyes and glands (P=0.87 and P=0.92) Acute inflammation was seen in 1 Harderian gland that received γ-cyclodextrin nanoparticle eye drops×2/day. The difference in conjunctival injection between the groups was nonsignificant (P=0.30).
  
  
  CONCLUSIONS
  Dorzolamide γ-cyclodextrin nanoparticle eye drops are no more locally toxic or irritating to the eye than Trusopt.
authors.affiliation: 1 Department of Ophthalmology, National University Hospital, University of Iceland , Reykjavik, Iceland .
authors.forename: Gauti
authors.initials: G
authors.lastname: Jóhannesson
authors.forename: Maria D
authors.initials: MD
authors.lastname: Moya-Ortega
authors.forename: Gudrun Marta
authors.initials: GM
authors.lastname: Asgrímsdóttir
authors.forename: Bjarni A
authors.initials: BA
authors.lastname: Agnarsson
authors.forename: Sigrún H
authors.initials: SH
authors.lastname: Lund
authors.forename: Thorsteinn
authors.initials: T
authors.lastname: Loftsson
authors.forename: Einar
authors.initials: E
authors.lastname: Stefánsson
mesh_terms: D000818:Animals; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000633:toxicity*; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D006243:Harderian Gland / Q000187:drug effects / Q000473:pathology; D007249:Inflammation / Q000139:chemically induced / Q000473:pathology; D053758:Nanoparticles; D009883:Ophthalmic Solutions; D011817:Rabbits; D013449:Sulfonamides / Q000008:administration & dosage / Q000633:toxicity*; D013876:Thiophenes / Q000008:administration & dosage / Q000633:toxicity*; D047408:gamma-Cyclodextrins / Q000737:chemistry*
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D003692:Delayed-Action Preparations; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; D047408:gamma-Cyclodextrins; C062765:dorzolamide; C023792:gamma-cyclodextrin